Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT.
AXUMIN vs TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
Technetium Tc 99m albumin aggregated is a radiopharmaceutical that localizes in the pulmonary capillary bed by capillary blockade, allowing for lung perfusion imaging. The aggregated albumin particles are trapped in the pulmonary capillaries, and the Tc 99m emits gamma radiation detectable by gamma cameras.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
1-4 mCi (37-148 MBq) intravenous injection for lung perfusion imaging. Single dose per imaging session.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Physical half-life of Tc-99m is 6.02 hours; biological half-life of aggregated albumin in lungs is 2-4 hours due to enzymatic degradation and clearance.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Renal: 30-40% within 24 hours (free pertechnetate); fecal: <1% (minor); remainder accumulated in reticuloendothelial system with slow release.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical